Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1994 165
1995 177
1996 178
1997 145
1998 190
1999 161
2000 207
2001 158
2002 251
2003 251
2004 245
2005 224
2006 205
2007 191
2008 132
2009 230
2010 221
2011 223
2012 252
2013 295
2014 237
2015 196
2016 210
2017 203
2018 183
2019 165
2020 139
2021 106
2022 109
2023 137
2024 155
2025 176
2026 126

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

5,310 results

Results by year

Filters applied: . Clear all
Page 1
Evidence-based clinical practice guidelines for cholelithiasis 2021.
Fujita N, Yasuda I, Endo I, Isayama H, Iwashita T, Ueki T, Uemura K, Umezawa A, Katanuma A, Katayose Y, Suzuki Y, Shoda J, Tsuyuguchi T, Wakai T, Inui K, Unno M, Takeyama Y, Itoi T, Koike K, Mochida S. Fujita N, et al. J Gastroenterol. 2023 Sep;58(9):801-833. doi: 10.1007/s00535-023-02014-6. Epub 2023 Jul 15. J Gastroenterol. 2023. PMID: 37452855 Free PMC article. Review.
Gastric intestinal metaplasia: progress and remaining challenges.
Tong QY, Pang MJ, Hu XH, Huang XZ, Sun JX, Wang XY, Burclaff J, Mills JC, Wang ZN, Miao ZF. Tong QY, et al. J Gastroenterol. 2024 Apr;59(4):285-301. doi: 10.1007/s00535-023-02073-9. Epub 2024 Jan 19. J Gastroenterol. 2024. PMID: 38242996 Review.
First-line biologics as a treatment for ulcerative colitis: a multicenter randomized control study.
Naganuma M, Shiga H, Shimoda M, Matsuura M, Takenaka K, Fujii T, Yamamoto S, Matsubayashi M, Kobayashi T, Aoyama N, Saito D, Yokoyama K, Moriya K, Tsuchiya K, Shibui S, Kawamoto A, Shimizu H, Okamoto R, Sakamoto K, Yaguchi K, Kunisaki R, Akiyama S, Hayashi R, Hasui K, Kanmura S, Bamba S, Mishima Y, Kakimoto K, Sugimoto S, Nakazawa A, Abe T, Ogata H, Hisamatsu T; Collaborators of the Study. Naganuma M, et al. J Gastroenterol. 2025 Apr;60(4):430-441. doi: 10.1007/s00535-025-02216-0. Epub 2025 Jan 30. J Gastroenterol. 2025. PMID: 39883201 Clinical Trial.
Acknowledgements.
[No authors listed] [No authors listed] J Gastroenterol. 2025 Mar;60(3):392-395. doi: 10.1007/s00535-025-02229-9. J Gastroenterol. 2025. PMID: 39982459 No abstract available.
Proposal of discontinuation criteria of atezolizumab plus bevacizumab after curative conversion therapy for unresectable early-to-intermediate-stage hepatocellular carcinoma: a multicenter proof-of-concept study.
Aoki T, Kudo M, Nishida N, Ueshima K, Tsuchiya K, Tada T, Morita M, Chishina H, Takita M, Hagiwara S, Ida H, Minami Y, Kuroda H, Nakamura N, Hiraoka A, Tomonari T, Tani J, Naganuma A, Kakizaki S, Ogawa C, Hatanaka T, Ishikawa T, Kawata K, Takebe A, Matsumoto I, Hidaka M, Kurosaki M, Kumada T, Izumi N. Aoki T, et al. J Gastroenterol. 2025 Jun;60(6):738-753. doi: 10.1007/s00535-025-02233-z. Epub 2025 Mar 7. J Gastroenterol. 2025. PMID: 40055288 Free PMC article.
5,310 results